thiamine has been researched along with Encephalopathy, Toxic in 12 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 7.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| " Chronic use of ethanol often leads to the development of neurodegenerative syndromes, which cause morphological and functional impairments such as foetal alcohol syndrome in newborns exposed to ethanol during pregnancy, Wernicke-Korsakoff Syndrome and, more rarely, Marchiafava-Bignami disease (MBD)." | 6.55 | Thiamine deficiency, oxidative metabolic pathways and ethanol-induced neurotoxicity: how poor nutrition contributes to the alcoholic syndrome, as Marchiafava-Bignami disease. ( Bezerra, FR; de Oliveira, FR; Fernandes, LMP; Fontes-Júnior, EA; Lima, RR; Maia, CSF; Monteiro, MC; Silva, ML, 2017) |
| "To determine whether thiamine prophylaxis decreases the incidence of ifosfamide-induced encephalopathy in patients receiving ifosfamide for the treatment of lymphoma." | 3.96 | Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. ( Ayarza, M; Clark, SM; Hairston, A; Lentz, KL; Liu, B; Morgan, KP; Wind, LS, 2020) |
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 3.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| " Chronic use of ethanol often leads to the development of neurodegenerative syndromes, which cause morphological and functional impairments such as foetal alcohol syndrome in newborns exposed to ethanol during pregnancy, Wernicke-Korsakoff Syndrome and, more rarely, Marchiafava-Bignami disease (MBD)." | 2.55 | Thiamine deficiency, oxidative metabolic pathways and ethanol-induced neurotoxicity: how poor nutrition contributes to the alcoholic syndrome, as Marchiafava-Bignami disease. ( Bezerra, FR; de Oliveira, FR; Fernandes, LMP; Fontes-Júnior, EA; Lima, RR; Maia, CSF; Monteiro, MC; Silva, ML, 2017) |
| " TPP, especially at a dosage of 20 mg/kg, significantly reduced TBARS and MPO levels that increase with cisplatin administration compared with the thiamine group, while TPP significantly increases GSH and SOD levels." | 1.40 | An investigation of the effect of thiamine pyrophosphate on cisplatin-induced oxidative stress and DNA damage in rat brain tissue compared with thiamine: thiamine and thiamine pyrophosphate effects on cisplatin neurotoxicity. ( Cayir, A; Cetin, N; Siltelioglu Turan, I; Suleyman, H; Tan, H; Turan, MI, 2014) |
| "A serious adverse effect that can limit the utility of ifosfamide is neurotoxicity, known as ifosfamide-induced encephalopathy (IIE)." | 1.37 | Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. ( Marshall, H; McQuary, A; Richards, A, 2011) |
| " Here we demonstrated that these toxic exposures were accompanied by an early marked reduction in both pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase activities, followed by a decrease in neuronal mitochondrial transmembrane potential and ATP, prior to murine cortical neuronal death." | 1.33 | Free radical-mediated neurotoxicity may be caused by inhibition of mitochondrial dehydrogenases in vitro and in vivo. ( Sheline, CT; Wei, L, 2006) |
| "Thiamine appears to be a safe and effective treatment for reversing encephalopathy resulting form ifosfamide infusion, without any significant side effects." | 1.33 | Role of thiamine in managing ifosfamide-induced encephalopathy. ( Awan, F; Hamadani, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lentz, KL | 1 |
| Clark, SM | 1 |
| Ayarza, M | 1 |
| Liu, B | 1 |
| Morgan, KP | 1 |
| Wind, LS | 1 |
| Hairston, A | 1 |
| Turan, MI | 1 |
| Cayir, A | 1 |
| Cetin, N | 1 |
| Suleyman, H | 1 |
| Siltelioglu Turan, I | 1 |
| Tan, H | 1 |
| Fernandes, LMP | 1 |
| Bezerra, FR | 1 |
| Monteiro, MC | 1 |
| Silva, ML | 1 |
| de Oliveira, FR | 1 |
| Lima, RR | 1 |
| Fontes-Júnior, EA | 1 |
| Maia, CSF | 1 |
| Lombardi, G | 1 |
| Zustovich, F | 1 |
| Nicoletto, MO | 1 |
| Donach, M | 1 |
| Pastorelli, D | 1 |
| Liu, YL | 1 |
| Tsai, SH | 1 |
| Chang, FW | 1 |
| Yu, MH | 1 |
| Richards, A | 1 |
| Marshall, H | 1 |
| McQuary, A | 1 |
| Imtiaz, S | 1 |
| Muzaffar, N | 1 |
| Piao, F | 1 |
| Ma, N | 1 |
| Yamamoto, H | 1 |
| Yamauchi, T | 1 |
| Yokoyama, K | 1 |
| Sheline, CT | 1 |
| Wei, L | 1 |
| Hamadani, M | 1 |
| Awan, F | 1 |
| Anetor, JI | 1 |
| Ajose, OA | 1 |
| Adebiyi, JA | 1 |
| Akingbola, TS | 1 |
| Iyanda, AA | 1 |
| Ebesunu, MO | 1 |
| Babalola, OO | 1 |
| Aadeniyi, FA | 1 |
| Yip, SF | 1 |
| Yeung, YM | 1 |
| Tsui, EY | 1 |
1 review available for thiamine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Thiamine deficiency, oxidative metabolic pathways and ethanol-induced neurotoxicity: how poor nutrition contributes to the alcoholic syndrome, as Marchiafava-Bignami disease.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Marchiafava-Bignami Disease; Neurotoxicity Syndromes; Oxidati | 2017 |
11 other studies available for thiamine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cohort Studies; Etoposi | 2020 |
An investigation of the effect of thiamine pyrophosphate on cisplatin-induced oxidative stress and DNA damage in rat brain tissue compared with thiamine: thiamine and thiamine pyrophosphate effects on cisplatin neurotoxicity.
Topics: Animals; Antineoplastic Agents; Cerebrum; Cisplatin; DNA Damage; Injections, Intraperitoneal; Lipid | 2014 |
Important role of thiamine in preventing ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Middl | 2010 |
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne | 2010 |
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity.
Topics: Adult; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; Methylene Blue; Middle Aged; | 2011 |
Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne | 2010 |
Effects of prednisolone and complex of vitamin B1, B2, B6 and B12 on organophosphorus compound-induced delayed neurotoxicity.
Topics: Animals; Chickens; Female; Neurotoxicity Syndromes; Organophosphorus Compounds; Prednisolone; Random | 2004 |
Free radical-mediated neurotoxicity may be caused by inhibition of mitochondrial dehydrogenases in vitro and in vivo.
Topics: Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Cerebral Cortex; Drug Interactions; Em | 2006 |
Role of thiamine in managing ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Male; Middle Aged; Neuro | 2006 |
Decreased thiamine and magnesium levels in the potentiation of the neurotoxicity of lead in occupational lead exposure.
Topics: Adult; Calcium; Humans; Lead; Lead Poisoning; Magnesium; Male; Middle Aged; Models, Chemical; Nervou | 2007 |
Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency.
Topics: Arsenic; Diet, Vegetarian; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Ag | 2002 |